TY - JOUR
T1 - Role of biomarkers to predict outcomes and response to therapy
AU - Lotan, Yair
PY - 2010/1
Y1 - 2010/1
N2 - Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.
AB - Molecular markers are not established in management of bladder cancer. There is, however, a limit to the ability of clinical and pathological parameters to predict patients at high risk for urothelial carcinoma of the bladder (UCB) recurrence or mortality. The assessment of molecular biomarkers in surgical UCB specimens offers additional information on the biology of the disease, and might improve the prediction of oncologic end points. There is also a potential for molecular biomarkers to predict the response to adjuvant or neoadjuvant therapies. Furthermore, markers may guide targeted therapy. Prospective trials are needed to validate the clinical benefit of assessing expression patterns of molecular biomarkers.
KW - Bladder cancer
KW - Molecular markers
UR - http://www.scopus.com/inward/record.url?scp=72549108182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72549108182&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2009.03.017
DO - 10.1016/j.urolonc.2009.03.017
M3 - Review article
C2 - 20123357
AN - SCOPUS:72549108182
SN - 1078-1439
VL - 28
SP - 97
EP - 101
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -